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Considerationss u m m a r y
Objective: There are few guidelines for clinical trials of interventions for prevention of post-traumatic
osteoarthritis (PTOA), reﬂecting challenges in this area. An international multi-disciplinary expert
group including patients was convened to generate points to consider for the design and conduct of
interventional studies following acute knee injury.
Design: An evidence review on acute knee injury interventional studies to prevent PTOA was presented
to the group, alongside overviews of challenges in this area, including potential targets, biomarkers and
imaging. Working groups considered pre-identiﬁed key areas: eligibility criteria and outcomes, bio-
markers, injury deﬁnition and intervention timing including multi-modality interventions. Consensus
agreement within the group on points to consider was generated and is reported here after iterative
review by all contributors.
Results: The evidence review identiﬁed 37 studies. Study duration and outcomes varied widely and 70%
examined surgical interventions. Considerations were grouped into three areas: justiﬁcation of inclusion
criteria including the classiﬁcation of injury and participant age (as people over 35 may have pre-existing
OA); careful consideration in the selection and timing of outcomes or biomarkers; deﬁnition of the in-
tervention(s)/comparator(s) and the appropriate time-window for intervention (considerations may be
particular to intervention type). Areas for further research included demonstrating the utility of patient-
reported outcomes, biomarkers and imaging outcomes from ancillary/cohort studies in this area, and
development of surrogate clinical trial endpoints that shorten the duration of clinical trials and are
acceptable to regulatory agencies.
Conclusions: These considerations represent the ﬁrst international consensus on the conduct of inter-
ventional studies following acute knee joint trauma.
© 2019 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Osteoarthritis (OA) pathologically represents a continuum from
risk exposure, to molecular changes and structural changes with
associated pain, which for some people progresses to the need for
joint replacement. Detection and treatment of those at high risk of
OA could enable effective interventions before any major struc-
tural damage has occurred or before pain becomes chronic, that is
at a pre-radiographic or even pre-symptomatic stage. Such inter-
vention would be comparable to current early management of
diabetes, cardiovascular disease, osteoporosis or pre-rheumatoid
arthritis.
Joint injury remains one of the biggest risk factors for OA. In
Sweden, approximately 80/100,000 people per year experience
anterior cruciate ligament (ACL) rupture; in the U.S. there are
252,000 ACL injuries per year1,2. 50% of people with signiﬁcant
knee joint injuries such as ACL rupture and/or acute meniscal tear
subsequently develop symptomatic radiographic OA within 10
years, so-called post-traumatic OA (PTOA)3; at least 33% with acute
ACL rupture will have magnetic resonance imaging (MRI)-deﬁned
whole joint OA after 5 years4. PTOA is thought to comprise around
12% of all OA, although its incidence appears to be increasing5,6.
However, there are no speciﬁc guidelines for clinical trials which
seek to measure the effect of interventions for prevention of OA
after an injury7,8. There are a number of challenges in study design
speciﬁc to this area, especially the potentially long study duration
needed. As such, regulatory considerations include the identiﬁca-
tion of surrogate outcomes for PTOA studies and the creation of a
new indication: OA prevention. This has led to signiﬁcant uncer-
tainty for regulatory agencies and drug developers, and has
restrained investments by the pharmaceutical industry.
An international expert working group was therefore convened
with the following aims: to review the literature on existing
interventional studies close to the time of knee injury; give an
overview of key areas in the ﬁeld relevant to future interventional
studies; deﬁne considerations for the conduct and design of trialsaimed at prevention of OA; and to highlight knowledge gaps by
developing research recommendations in this area.
Methods
The considerations process was facilitated by the Osteoarthritis
and Crystal Diseases Clinical Studies Group of Arthritis Research UK
(UK's largest arthritis charity), which was established to develop
consensus research priorities and nurture methodologically robust
clinical trials.
Whilst preventing joint injury is an intervention to prevent
PTOA7, our focus was on interventions after knee joint trauma. We
conducted an evidence review, then consensus process developing
considerations and a research agenda. Though the evidence review
summarized the use of outcome measures including patient re-
ported outcome measures (PROMs), no recommendations for
speciﬁc outcome measures were planned.
Evidence review
An evidence review was conducted to identify experimental,
interventional studies following acute knee injury with speciﬁc
reference to post-traumatic knee OA. Systematic searches were
conducted across ﬁve databases (Cochrane Library; EMBASE;
MEDLINE; CINAHLPlus; AMED) from inception to August 2016. The
search strategy was designed in OVID-Medline using text words
and subject headings (MeSH), combining terms for knee injury,
osteoarthritis and clinical trials or systematic reviews
(Supplementary Table 1).
All references were imported into Endnote where duplicates
were removed. Screening and study detail extraction was by NC,
veriﬁed by three others (FW, DM, PC). Study inclusion criteria were
as follows: population clearly stated within 6 months of acute knee
injury (any setting); interventional study (any intervention,
including surgical, pharmacological, non-pharmacological) with
any comparator (including active, placebo, sham or no
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domized controlled trials (RCTs), non-randomized controlled trials
or systematic reviews. Study exclusion criteria included: ‘acute’
injury not clearly separated from ‘chronic’, or from other joint
disease; non-English-language articles; letters, comments or edi-
torials. Observational studies of interventions in this area were not
included in our evidence search or considerations, as they were felt
to be prone to bias and not representative of our main focus which
related to experimental studies.
Consensus group
A group of 32 stakeholders, including physiotherapists, ortho-
paedic surgeons, rheumatologists, sports and exercise medicine
physicians, primary care physicians, radiologists, laboratory scien-
tists, statisticians, clinical trialists, engineers, pharmaceutical com-
panyexperts and four patient representatives (2whohad a previous
knee joint injury) comprised the consensus group. After the evi-
dence review results were circulated, the group convened at a face-
to-face meeting. The evidence review, which included a summary
on the use of PROMs, was presented and overviews of literature-
identiﬁed key areas were given by invited experts: challenges
around studies in this area (Lohmander), molecular biomarkers
(Kraus) and imaging (Roemer). Speciﬁc case study examples of po-
tential interventional targets and challenges were presented (Ma-
son, Kraus). Three working groups with facilitators and reportersTable I
Overview of basic study details, categorized according to type of knee injury
ACL Patellar
Dislocation
T
f
Number of studies [papers if
different]
20 [40 papers incl. 11 conf.
abstracts]
8 [9 papers, incl. 1
abstract only]
7
RCT/nRCT RCT: 20 incl. 1 protocol
and 1 pilot
RCT: 7 nRCT: 1 R
Sample size at randomization
Missing 1
<20 2
20-50 5 5 4
>50e100 7 2 2
>100e200 5 1 1
Power calculation
a priori 9 5 2
post hoc 2
None 8 2 3
Unclear 1 1 2
Study adequately powered
(based on sample size)
9 of 9 4 of 5 2
Study duration
Missing 1 1
<3 months 1
3e6 month 3
>6 monthse1 year 3 3
>1e2 years 4 3
>2e5 years 3 2
>5e10 years 2 3
>10 years 4 1 1
Primary outcome measure(s)
clearly deﬁned
9 þ 1 used for sample
size calculation
5 2
s
Type of interventions
Surgical vs Surgical 10 7
Surgical vs Other 1 8
Other vs Other 3
Pharmacological vs
Pharmacological
2 (all placebo)
Post-op Rehab vs Post-op Rehab 2
Post-op Pharma vs Post-op Pharma 1
Post-op Pharma vs No intervention 1
ACL ¼ Anterior cruciate ligament.
RCT ¼ Randomized controlled trial.
nRCT ¼ non-randomized controlled trial.were convened to consider: A: Eligibility criteria and choice of
outcomes, B: The use of biomarkers (including soluble biomarkers
and imaging) as potential stratiﬁers or outcomes, and C: Deﬁnition
of the injury, the timing of intervention, and considerations for
multi-modality interventions. Written notes were compiled, pre-
sented by each group's reporter to all stakeholders and agreement
on items and additional overarching points to consider were
generated during a ﬁnal discussion session, chaired by PC, with
written statements agreed by all (facilitated by FW). The meeting
was taped and transcribed; any uncertainties were addressed
from the transcript. Subsequently, the document and then manu-
script was reviewed by all contributors through an iterative online
process.
Results
Evidence review
The initial search identiﬁed 2476 citations (MEDLINE, n ¼ 532;
EMBASE, n ¼ 863; CINAHLPlus, n ¼ 489; AMED, n ¼ 60; Cochrane
Library, n ¼ 532). 945 duplicates were removed. Screening of the
remaining 1531 abstracts yielded 43 eligible studies. Seven sys-
tematic reviews identiﬁed a further 15 reported trials. From these
58 papers (including 11 conference abstracts), 37 unique studies
were included. Details of each study are summarized in
Supplementary Table 2. The majority of studies involved ACL injuryibial plateau
racture
Other Total
incl. 2 abstract only 2 studies 37 [58 papers incl. 11 conf.
abstracts & three abstracts only]
CT: 6 incl. 1 protocol nRCT: 1 RCT: 2 incl. 1 pilot RCT: 35 incl. 2 pilots, 2 protocol;
nRCT: 2
1
1 3
14
11
1 8
16
1 3
1 14
4
of 2 15 of 16
2
1 2
3
1 7
7
5
5
6
þ 1 used for sample
ize calculation
1 17 þ 2 based on sample size
calculation
17
9
3
1 (placebo) 3: all placebo controlled
1 3
1
1
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fracture (n ¼ 7; 19%), with the remaining two studies including any
‘acute knee injury’.
Table I summarizes the basic study details grouped according
to type of injury. All but two studies were RCTs (n ¼ 35; 95%). Of
16 studies reporting power calculations, 15 met or exceeded the
sample size required (Supplementary Table 2). Study duration
varied widely, approximately equally distributed across 0e1
years, >1e5 years and >5 years. Most studies (70%) compared a
surgical intervention against either another surgical or non-
surgical/non-pharmacological (henceforth referred to as ‘other’)
intervention. Comparisons of post-operative rehabilitation in-
terventions, pharmacological studies (the only studies to use a
placebo arm) and all other interventions each accounted for ~8%
of all studies (Table I).
An overview of inclusion and exclusion criteria for all available
full-text papers (n ¼ 32) is shown in Supplementary Table 3. Most
studies (88%) had clearly deﬁned eligibility criteria. Sixty percent
provided a speciﬁc age range, spanning 13e50 years old. Sex was a
speciﬁed criterion in only three studies, one of which excluded
females. Elite professional sports activity and pregnancy were ex-
clusions in 20% of studies.
Pre-existing conditions or other concomitant injuries excluded
patients in 80% of studies. For example, previous index (and
sometimes contralateral) knee injury and/or surgery were exclu-
sions in >60% of studies and the presence of OA was an exclusion
criterion in 25% of studies (Supplementary Tables 3 and 4).
One-hundred-and-forty-seven outcome measures were iden-
tiﬁed (Table II), including physical examination outcomes
(n ¼ 30), patient-reported outcomes (n ¼ 26) of which the Knee
Injury and Osteoarthritis Outcome Score (KOOS) was most
frequently used5, imaging outcomes (n ¼ 43), biomarkers (n ¼ 39)
and other (n ¼ 9) (Supplementary Tables 5e9 respectively).Table II
Summary of outcome measures
Outcome measure
category (n*)
Primary outcomes
Physical examination
n ¼ 30
1. Laxity (n ¼ 4)
2. Patellofemoral stability (n ¼ 2)
3. Limb symmetry indices (n ¼ 1)
4. Torque (n ¼ 1)
5. Muscle electrical activity (n ¼ 1)
6. Functional e hop test (n ¼ 1)
Patient reported
n ¼ 26
1. Knee injury and Osteoarthritis Outcome Score
(KOOS) (n ¼ 5)
2. Hospital for Special Surgery (HSS) knee score (n ¼ 2)
3. International Knee Documentation Committee (IKDC)
Subjective Knee Form (n ¼ 2)
4. Kujala score (n ¼ 2)
5. The Knee Self-Efﬁcacy Scale (K-SES) (n ¼ 1)
6. The Physical Activity Scale (n ¼ 1)
7. Tegner activity score (n ¼ 1)
8. Multidimensional Health Locus of Control (n ¼ 1)
Imaging n ¼ 43 1. Radiographic: KellgreneLawrence classiﬁcation
(n ¼ 1)
2. CT: Quality of reduction (n ¼ 1)
3. MRI: Morphologic measures of articulating
bone curvature (femur, tibia & trochlea) (n ¼ 1)
4. MRI: Cartilage thickness of femorotibial medial
compartment (n ¼ 1)
5. MRI: Anterior Cruciate Ligament Osteoarthritis
Score (ACLOS) (n ¼ 1)
Biomarkers (n ¼ 39) 1. GAG/proteoglycan marker: ARGS-aggrecan (n ¼ 1)
Other (n ¼ 9) 2. Safety, tolerability & adverse effects (n ¼ 1)
TOTAL n ¼ 147 Total ¼ 21 primary outcomes
*where n ¼ total number of studies with such measures.Primary outcome measures were identiﬁed by only 19 studies
(Tables I and II). Ten different OA outcomes included nine imaging
structural measures and one surrogate measure, KOOS (Table II,
Supplementary Tables 6 and 7). Only ﬁve studies (of ACL rupture
subjects) used molecular biomarkers as outcome measures
(Supplementary Table 8).
Summary of key area discussions
Molecular pathogenesis and biomarkers of the injury response
Recently there has been an increase in our understanding of
the molecular pathogenesis of PTOA. Observations from both
humans and animal models reveal that diverse signalling path-
ways (involving inﬂammation, apoptosis and cell senescence) are
activated by injury9,10. This activation is associated with subse-
quent bone remodelling, cartilage matrix damage and synovial
inﬂammation11,12. Synovial ﬂuid at the time of joint injury shows
marked increases in pro-inﬂammatory cytokines (e.g., IL-6 is
1000-fold up-regulated) and within 2 weeks shows evidence of
matrix catabolism of both aggrecan and type II collagen13e15. The
response appears to differ between individuals, and is repre-
sented by a tissue inﬂammatory response, primarily detectable in
the synovial ﬂuid13,14,16. Following injury, a variety of factors may
encourage joint homeostasis and resolution (including normal
physiological loading), or progression to post-traumatic OA
(including excessive loading or further injury). Further injury or
surgery would appear to prolong the inﬂammatory response to
trauma17. There may be an ‘early therapeutic window’ following
joint injury during which inﬂammatory response genes are up-
regulated and matrix degradation is initiated which could be
targeted by intervention18. The optimal and/or latest times at
which degradation could be halted or reversed are currently
unknown.Osteoarthritis and surrogate OA outcomes
1. Knee injury and Osteoarthritis Outcome Score (KOOS) (n ¼ 1)
1. Radiographic: Study speciﬁed criteria incl. joint space narrowing,
osteophyte grade, subchondral sclerosis and sharpening of tibial
spines (n ¼ 4)
2. Radiographic: KellgreneLawrence classiﬁcation (n ¼ 4)
3. Radiographic: Ahlb€ack classiﬁcation (n ¼ 2)
4. Radiographic: modiﬁed OARSI grading scale for OA (n ¼ 1)
5. Radiographic: Medial joint space width (n ¼ 1)
6. Radiographic: Ahlb€ack & Fairbank composite scale (n ¼ 1)
7. MRI: Whole Organ Magnetic Resonance Imaging Score (WORMS) (n ¼ 1)
8. MRI: Anterior Cruciate Ligament Osteoarthritis Score (ACLOAS) (n ¼ 1)
9. qMRI: Early matrix changes typical of arthritis (n ¼ 1)
Total ¼ 10 measures
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Much work on OA pathogenesis has been accomplished in ani-
mal models, which exploit the association between joint injury and
OA, using trauma or surgically-induced injury to predictably induce
disease: they are therefore particularly suited to testing early in-
terventions in this setting. Findings from murine models such as
those involving destabilization of the medial meniscus appear to
translate to human studies of ACL rupture or meniscal tear14. The
effects of suppressing certain key pathways in these models have
been described in knockout mice19. Despite this, very few in-
terventions have been tested at the time of injury, in rodents or in
man, as opposed to established OA, which could account for some
of the failure of translation of OA therapeutics to date.
However, there may be some molecular differences as well as
some practical challenges in the testing of intra-articular agents in
small animals and in the extrapolation of optimal timing of an
intervention from rodent to man.
Examples of potential pharmacological targets
Glutamate concentrations are increased in synovial ﬂuid of
arthritic joints in humans and animals, activating glutamate re-
ceptors on neurones and synoviocytes to induce pain and cause
release of IL-620,21. Intra-articular inhibition of a-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA) and kainate glutamate
receptors at the time of injury or induction of arthritis in rodent
models alleviates pain, inﬂammation and joint degeneration22,23.
IL-1 causes cartilage degradation in vitro and is upregulated in sy-
novial ﬂuid following joint injury24,25. Blockade of this pathway
(with IL1-receptor antagonist (IL1RA)) reduced inﬂammation and
degeneration in a mouse model of arthritis26. IL-1 or AMPA/kainate
receptors represent potential therapeutic targets for preventing
later disease, as their inhibition at the time of injury in models of
post-traumatic OA reduced disease. IL1RA is the ﬁrst therapeutic
agent to be tested in human pilot studies at the time of knee injury
for this indication27. A further example is a small RCT testing steroid
injection within 4 days of ACL tear, where the collagen degradation
biomarker CTX-II was signiﬁcantly reduced in synovial ﬂuid in the
steroid-treated arms15. Since AMPA/kainate receptor antagonists,
IL1RA and steroids are already used in man, re-purposing of
existing agents is a real possibility.
Imaging in acute injuries
Imaging-based change following knee injury reﬂects the initial
trauma but also the responses to subsequent changed dynamic
knee loading after destabilizing injuries28. The majority of studies
include X-ray and MRI cartilage outcomes, both semi-quantitative
and quantitative. Although there are a few high-quality longitudi-
nal imaging studies after ACL rupture, more studies are needed. It is
possible to deﬁne early OA on either X-ray or MRI, and evidence
indicates that MRI changes alone can act as an endpoint29.
Depending on the target, non-cartilage MR outcomes, either bone-
based, such as bone marrow lesions (BMLs) or synovitis-effusion,
may be appropriate. Compositional measures using MRI, positron
emission tomography (PET) or computed tomography (CT) remain
investigational. Composite metric sequences including T1r and T2
have been associated with the PROM KOOS, pain after ACL recon-
struction and with synovial ﬂuid biomarkers at the time of sur-
gery30e32. Change in these compositional measures may reﬂect
differences in surgical factors after ACL reconstruction and the pre-
injury joint structure33.
Consistent changes in cartilage thickness occur after ACL
rupture: two cartilage regions quickly increase in thickness over
time, whilst other areas decrease34. Within 3 months of ACL injury,
there are marked changes in knee bone curvature35. Patellofemoral
joint (PFJ) OA appears more prevalent in cohort studies, particularlyrelating to ACL rupture/reconstruction; however, the PFJ is not al-
ways examined by X-ray.
Structural changes generally develop slowly, and traumatic and
degenerative changes must be clearly separated, although may
appear similar (as in the case of BMLs). Common OA assessment
semi-quantitative instruments are only partially applicable in this
setting: Whole Organ Magnetic Resonance Imaging Score
(WORMS), BLOKS and MOAKS do not differentiate between trau-
matic and degenerative joint changes, and do not include assess-
ment of post-surgical graft integrity36. Anterior Cruciate Ligament
Osteoarthritis Score (ACLOAS) is a new tool which addresses some
of these issues including clear differentiation of traumatic from
degenerative BMLs, extent of baseline traumatic osteochondral
damage and assessment of the graft37.
Imaging biomarkers predicting OA
A systematic review in this area reported that meniscal lesions,
meniscectomy, BMLs, time from injury and altered biomechanics all
are associated with cartilage loss over time after ACL rupture38.
Greater cartilage damage at baseline is associated with worse
clinical outcome (although this could represent pre-existing
OA)39e41. Presence of cortical depression fractures is associated
with a worse International Knee Documentation Committee (IKDC)
score at 1 year42. MRI-detected inﬂammation markers (effusion-
synovitis/Hoffa-synovitis) at 2 years after ACL rupture were asso-
ciated with OA development at 5 years43. Effusion, or presence of
BMLs at 1 year, or meniscal tears at any stage were found to be
associated with radiological OA at 2 years39. Early bone curvature
change is predictive of cartilage loss at 5 years and accentuated by
the presence of meniscal injury35.
Points to consider
These are summarized under overarching considerations and
three main areas: eligibility criteria, outcome measures and deﬁ-
nition and timing of interventions and comparators in these
studies.
Overarching considerations
Key overarching considerations are included in Table III. It was
emphasized that a better understanding of disease pathogenesis
was important. The appropriate time-window, role and effects of a
proposed intervention on underlying processes such as inﬂam-
mation, mechanical loading and subsequent bone or cartilage
change need to be elucidated. Some ﬁndings may usefully be
translated from animal models; however, it was also noted that
there may be important differences between the response to acute
knee trauma and a discrete surgically-induced isolated injury to
ACL or meniscus. It was agreed that the considerations highlighted
in this paper should be reviewed periodically as more data become
available, with a maximum of 3 years before the next revision.
Eligibility criteria
Eligibility criteria should be clearly deﬁned and should identify
speciﬁc groups with a modiﬁable process following their injury in
which to test the intervention (Table IV).
Deﬁnition of injury. Examples of well-deﬁned groups based on MRI
to be includedwould be ACL tear combinedwith other injuries such
as traumatic meniscal tear (although different outcomes are
probably associated with medial or lateral tears)44, or chondral
damage/cortical depression fracture42. Degenerative meniscal le-
sions should be considered part of early OA and not included in
acute post-trauma studies45. 55% of patients sustain simultaneous
injuries to both ACL and meniscus46; the ubiquitous biological
Table IV
Recommendations for points to consider: eligibility criteria
Consideration Recommendation
1. Deﬁnition of acute
knee injury
, The extent and characteristics of acute structural joint damage should be fully classiﬁed by magnetic resonance imaging
, Subgroups/types of injury for inclusion such as ACL and/or meniscal tear should be carefully deﬁned
, Different types of injury may be associated with different biomechanical outcomes and responsiveness to any given intervention, so the
target population needs to be carefully deﬁned
, In the case of meniscal tears, the individual's age, history of a clear injurious episode, plusMR appearances are all important in identifying
traumatic tears (and excluding degenerative lesions from these studies)
, Caution should be exercised in the inclusion of extreme phenotypes, for example those with isolated ACL tears or very extensive injuries
2. Time since injury , Establishing an appropriate therapeutic time-window will be relevant for each new target/intervention
, Certain interventions targeting the early response to injury may beneﬁt from being tested within days of injury, or up to a maximum of 4
e6 weeks from injury
3. Age , Upper age limit should be carefully considered; an upper age limit of 35 was proposed
, Challenges were highlighted around intervening in paediatric populations who lack capacity to give informed consent or who have
immature growth plates
4. Demographics , People of both sexes should be included
, Studies may include, but should not be restricted, to professional athletes
5. Proposed exclusions , Other existing causes of joint pathology
B inﬂammatory arthritis or pre-existing established osteoarthritis
B other disorders of bone, current or past
B previous substantial injury or surgery of index knee (particularly where there would be an associated markedly increased risk of
PTOA)
B other concomitant body injury or surgery (in some circumstances as may confound biomarkers)
, Pregnancy or breast-feeding
, Heavy use of alcohol, or recreational drug use
, Morbid obesity
Table III
Recommendations for points to consider: overarching considerations
Consideration Recommendation
1. General , Considerations should be relevant to the design of all forms of interventional study following joint injury, unless otherwise stated
, CONSORT or STROBE criteria should be adopted in the design and reporting of any interventional or cohort study in this area
, Patients and the public should be involved throughout the process of study design and delivery
2. Regulatory , Current and future regulatory considerations and requirements in this area should be considered in design of future studies
, The community should work closely with regulatory bodies to establish evidence and precedent for outcomes and design of
interventional trials
, Responder criteria, the number needed to treat for beneﬁt (NNT), and cost-effectiveness should be measured
3. Feasibility , Feasibility, patient burden and cost considerations of, for example, type of imaging, or intervening near to the injury should be carefully
weighed against the scientiﬁc/therapeutic beneﬁts of the proposed approach
, For any given study, a balance should be found between scientiﬁc rigour in design and pragmatic considerations regarding recruitment
and generalizability to clinical practice
4. Speciﬁc targets , Some of the considerations around study design (including eligibility criteria, outcomes and time-window of intervention) may be
different, depending on the nature of the intervention
, There may be particular biomarker(s) which are speciﬁc and sensitive for a particular intervention
5. Stratiﬁcation , The assessment of personal or individualized risk was noted to be important
, Novel molecular or imaging biomarkers might be used in the future as stratiﬁers at the point of entry to the study, or as intermediate
(surrogate) outcomes, but none are validated for these purposes currently
, Effective stratiﬁcation of an individual's personal risk of post-traumatic OA is not yet possible based on current knowledge
F.E. Watt et al. / Osteoarthritis and Cartilage 27 (2019) 23e3328response to joint tissues injury supports broader inclusion of injury
sub-types. Combined ligament injuries or fractures should not
necessarily be excluded but considered as a separate ‘extreme’
phenotype, as theymay be at substantially increased OA risk, which
may or may not be reversible.Time since injury. Some interventions may be most effective if
exerting their effect as soon as possible after the early biological
changes after injury. The appropriate time window for any inter-
vention after injury needs to be carefully justiﬁed, according to it's
nature.Age. Those less than 30 years are more likely to have purely trau-
matic meniscal lesions; those over age 35 could be at risk of pre-
existing OA/degenerative meniscal lesions.Demographics. Elite athletes are more likely to have past/repeated
injuries but may have different responses to injury compared tonon-elite individuals. As elite athletes are at high risk of OA, they
still represent a relevant subgroup for investigation.
Exclusions. Previous substantial knee injury or surgical procedure
to the index knee may confound results and should be considered
as a possible exclusion. BMI should be documented: excessive
obesity has independent effects on disease risk, joint loading and
inﬂammation.
Outcome measures
Key considerations are shown in Table V.
PROMs. In addition to the collection of longer-term PROMs,
repeated, multiple early measures will allow examination of po-
tential earlier surrogate endpoints in the future.
Imaging. Baseline and longitudinal evaluation should differentiate
pre-existing degenerative from acute traumatic structural joint
damage. The contralateral knee may subsequently be affected,
Table V
Recommendations for points to consider: outcome measures
Consideration Recommendation
1. General , Measures of symptoms and structure are both important and should be recorded
, The primary outcome measure(s) are likely to be required after 1e2 years after intervention but should relate to the study
question
, Short, medium and long term outcomes should be collected
, Frequent outcomes should be considered in the ﬁrst year, particularly for efﬁcacy and biomarker-related questions
2. Patient reported outcome
measures (PROMs)
, PROMs which have been validated within appropriate populations and which examine pain, function, performance and
quality of life were recommended
, The choice of tool should depend on its extent of validation and reliability as well as feasibility including cost
, Early assessment of the cost effectiveness of any given intervention, or interventions should be considered
3. Imaging , Imaging should be used a) to categorize and phenotype, and b) as an important outcome measure
, MRI and X-ray are both important outcome measures, but MRI may have increased sensitivity at earlier times after injury
, The patello-femoral joint and tibio-femoral joints should both be included in imaging assessments
, An index/signal knee should be deﬁned (given that the opposite side may subsequently be affected)
, The contralateral knee may be a useful imaging control or comparator for the index/signal knee
, The index/signal knee, and ideally both knees, should be imaged at 0 (baseline), 12 months and 24 months for structural
changes after intervention; inclusion of a later time point, such as 5 years was also recommended
, Morphology and change in all joint tissues should be captured, using validated semi-quantitative and/or quantitative
measures
, Compositional assessment at 6months for cartilage (MRI) or bone changes (MRI, PET, CT) is more experimental but should be
considered in addition to structural assessments
4. Molecular biomarkers , No speciﬁc biomarker(s) can be recommended for routine use in interventional studies
B Biomarkers cannot yet act as independent surrogate endpoints for early OA diagnosis
B Biomarkers have not been validated for aiding selection of patients for interventional studies
, Molecular biomarkers should be considered as exploratory outcome measures in interventional studies
B Choice(s) will depend on the target and outcomes under study
, Bio-samples (including synovial ﬂuid, in addition to serum/plasma and urine) should be collected in all future studies where
possible
B Serum and urine should be collected at all available time points
B Sampling should include DNA storage where appropriate consent is given
B Synovial ﬂuid can be accessed at the time of surgery or clinical aspiration, or at the time of drug delivery into the index/
signal knee
B Timing and method of sample collection must be consistent and standardized across all studied patients
5. Functional outcomes , Stability of the knee and muscle strength are important to patients, and potentially important outcome measures
, Symptoms of instability may have value in addition to examination-based measures of mechanical instability/laxity
, Other potential functional biomarkers include kinematics, hop or stair climbing tests and muscle co-contraction testing
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Considerations around type of imaging and its frequency include
evidence of speciﬁc outcome performance metrics, feasibility and
cost. Where trials are multi-center, MRI protocols need to be care-
fully designed (for example, compositional imaging may be chal-
lenging in a multi-center setting, and magnet strength should be
considered in the context of ACL reconstruction and metal artefact).
Selection of imaging biomarker (semi-quantitative or quantitative)
requires understanding of the validity, reliability and responsive-
ness of each measure. MRI techniques that assess early cartilage
changes may be useful. Measures of synovial or fat pad inﬂamma-
tion may be important for anti-inﬂammatory therapeutics and MRI
techniques that quantify synovitismay be considered. Early changes
in 3D bone shape seen after injury which predict subsequent OA
warrant further study as a potential surrogate endpoint.Molecular biomarkers. These were noted to be under development
as stratiﬁers and as outcome measures: none were yet sufﬁciently
evidence-based to act as independent surrogate measures as either
an early OA diagnostic, prognostic or patient selection aid for
interventional studies. Irrespective of target, to accelerate thera-
peutic advances, it is important that bio-samples be collected in all
cohorts and clinical trials where possible. DNA storage would allow
the international community to work collaboratively to identify
novel genetic predictors of outcome.
Synovial ﬂuid was highlighted as a potentially important bio-
sample, showing biologically important molecular changes after
injury and after intervention; synovial ﬂuid molecular changes are
likely to have increased utility compared to serum13e15. Contra-
lateral aspiration of synovial ﬂuid was controversial, as thecontralateral knee is not always a good control and it is difﬁcult to
aspirate normal joints. It is important that non-surgical studies
access synovial ﬂuid to avoid bias towards surgical intervention
studies. In some cohorts, serum/plasma/urine may be available
prior to the injury (e.g., participants in a biobank or military co-
horts): measuring change within an individual was noted as
analytically powerful. Regarding biomarker choice, the most qual-
iﬁed biomarkers to date, e.g., CTX-II, could be included if cartilage
matrix catabolism is a target; synovial inﬂammation or bone bio-
markers, or speciﬁc cytokine measurements may be relevant
depending on target27.
Functional outcomes. Symptoms of instability could be more reli-
able than any examination-based measures. However, their sensi-
tivity to change compared with existing measures such as pain
should be evaluated further47.
Deﬁnition and timing of intervention and comparator
The choice of timing of the intervention will depend on the
nature and mode of its action and intended effects, as well as the
measured outcome. An optimal ‘therapeutic window’ should be
carefully deﬁned for any intervention (Table VI), see also Eligibility
Criteria: ‘Time Since Injury’. It may be that identiﬁcation of high risk
phenotypes is possible by imaging or molecular biomarkers at
deﬁned times after the injury.
Types of intervention are highly varied; where multi-modality
interventions are used, these should be carefully deﬁned, and
controlled. Drugs could be given systemically or intra-articularly, as
single or multiple doses, dependent on agent and duration of
treatment, safety considerations and acceptability.
Table VI
Recommendations for points to consider: deﬁnition and timing of intervention and comparators
Consideration Recommendation
1. General , Optimal time-window for administration of any given intervention should be validated and clearly deﬁned
, Assumptions should be avoided; different proposed time-windows for intervention should be tested head to head in feasibility studies if
necessary, to ensure patient acceptability, recruitment and likely translation in to clinical care
2. Comparators , A comparator and/or placebo or sham arm should always be used where possible
B Choice will depend on whether study is efﬁcacy or pragmatic
B Patients should be randomized to intervention or comparator arms
B Assessment of acceptability of sham treatments, particularly when invasive, is paramount when considering design and feasibility
, Double blind protocols should be used where possible
, While double-blinding is not always possible, blinded observer/assessor almost always is
3. Multimodality
intervention
, Multi-modality interventions may be particularly suited to this area
B Such studies are very challenging to design and deliver and require expert input
B Choice of each component ideally requires a priori evidence of effect
, The interaction of different interventions is an important consideration in this area, given that multi-modal intervention is common in
clinical practice.
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because of the known substantial placebo effect in OA studies48.
The comparator will often be standard or usual care, rather than no
treatment and requires careful deﬁnition. Randomization and pla-
cebo control are important principles not only for pharmacological
interventions, but also for device and surgical studies, where a large
placebo effect would be anticipated and which is not otherwise
controlled49.
There are a number of practical considerations for successful
recruitment, randomisation strategies, the standardisation of the
intervention (particularly if surgical) and allocation concealment in
these types of studies, particularly when they are multi-site18. This
should be carefully considered during study design and a number
of existing OARSI recommendations in trials of prevention of joint
injury and of established OA are highly relevant here7,8,50,51.
Research recommendations
The particular challenges and questions highlighted as needing
further research are included in Table VII.Table VII
Research recommendations
Consideration Recommendation
1. General , To best deﬁne populations to be included in studies,
identifying
B Injuries which are easily deﬁned and categorize
B Injuries for which this risk is likely to be reversi
B Injuries particularly suited to different types of
, Further work to enable prediction/stratiﬁcation of ind
molecular biomarker proﬁling is needed
B These predictors should be examined alone but
, Further work on deﬁning the appropriate time-wind
B This may differ depending on the nature of the
2. Pre-clinical studies , The analogous nature of animal models of post-trau
interventional studies in human
, Animal models or experimental medicine studies in
optimal time-window and initial pharmacokinetics, t
3. Preparation for
translation
, Patient and public involvement should be sought
overtreatment and acceptability of different types of
, Feasibility studies are encouraged to address questio
Findings should be published, to enable shared know
4. Outcomes , Better evidence for the modality and timing of early
, Evidence to support the use of surrogate outcomes
linking these early outcomes to later disease risk
, Evidence for the recommendation of one or more PR
, Longer observational/cohort/clinical trials should be
B natural history of joint trauma and outcomes
B utility of molecular biomarkers
B relationship between PROMs, biomarkers and im
B relationship between early outcomes (at 1 or 2
, Close liaison with industry and with regulatory autho
indication in this areaPatient representatives highlighted concerns for the potential
for over-diagnosis or overtreatment in the absence of risk stratiﬁ-
cation, and further Patient and Public Involvement is encouraged in
this area now, and as the ﬁeld develops.
Further evidence is needed for which outcomes should be used
in this setting, and what measurement(s) (whether a molecular or
imaging biomarker or PROM) might act as an acceptable surrogate
short term outcome for future OA (given that 5e10 year interven-
tional trials are not feasible). Although these current considerations
address interventional studies, the consensus group acknowledged
that ancillary/cohort studies which establish associations between
PROMs, biomarkers and imaging outcomes could address key
knowledge gaps to provide evidence for future trials. The design of
these studies should be carefully considered and outcomes
appropriately powered, but they may include more exploratory
outcomes. Sensitive, speciﬁc early measures which might shorten
studies should be sought.
The Consensus group noted that animal studies can inform
human studies, and such programs were justiﬁable to facilitate
early translation of targets to humans.further work is needed to understand relative risk of OA in different injury types,
d and are at high risk of OA
ble
intervention
ividual risk of future OA at the time of injury, using clinical factors imaging and/or
also in combination
ow for intervention after joint injury is needed
proposed intervention and the population studied
matic OA was highlighted, and the potential to therefore support translational
human should be used to deﬁne the likely best delivery of an intervention, its
o support future clinical trials
, particularly around areas of assessing risk of disease, risk of harm, risk of
proposed interventions
ns speciﬁc to an intervention, acceptability to patients, and reﬁne best outcomes.
ledge.
imaging as an outcome measure is needed
of efﬁcacy is needed: clinical/PROMs-based, imaging-based or biomarker-based,
OMs with the best utility in this area should be sought
designed to collect information on:
aging outcomes
years) and later outcomes at 5e10 years
rities on the areas of outcomes research and clinical need is advised to achieve an
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Our review of the literature has highlighted a lack of conformity
in design of interventional studies in this area. Evidence from the
review and expert consensus has been synthesised in producing
these ﬁrst international considerations on the design and conduct
of interventional studies aiming at prevention of OA following
acute knee injury. Critical knowledge gaps limiting such trials have
been highlighted, and summarised as research recommendations.
These considerations are intended to underpin future guidelines as
this ﬁeld evolves. Collaborative working on cohort and feasibility
studies is needed to provide better evidence for interventional
study design.
Studies need to include those patients who are at the highest
risk, but whose risk is modiﬁable by the proposed intervention.
There was an awareness of the identity of extreme phenotypes,
such as combined ligament injuries, which may fall outside these
criteria. As in OA, predictive risk modelling is needed for knee
trauma52. A better understanding of underlying disease mecha-
nisms from both animal and human studies is needed. Under-
standing how related mechanisms such as inﬂammation and
mechanical loading of the joint after trauma contribute to either
resolution or progression to OA was deemed essential for the
development of new interventions.
The feasibility and acceptability of testing interventions in an
acute setting can be challenging. Informed consent for sham or
placebo treatments at the time of knee injury needs careful review
by patients, healthcare providers and trialists. Sham-controlled
trials including surgical trials are often needed to provide the
best possible level of evidence49. Recent consensus in classiﬁcation
of early knee OA will facilitate such trials53. Alternative surrogate
outcome measures need to be developed to shorten trial duration
and improve the likelihood of drugs being developed by industry.
MRI costs are relatively high, but may be justiﬁed by allowing re-
searchers to examine earlier outcomes. Whilst X-ray follow-upmay
appear more feasible, it's use as a lone imaging modality must be
adequately powered.
There are some limitations to the approach used. The literature
review was performed to provide evidence for discussions, rather
than as a stand-alone piece of work; it was clear after the initial
search that areas of interest, such as pharmacological in-
terventions, were not well represented in the current literature,
and limitations of generalizability to all types of interventions
should therefore be borne in mind. A critical appraisal of the
studies was not performed as it was not felt necessary for the re-
quirements of this review, which was pragmatic in nature. Given
the relatively low number of RCTs identiﬁed in this area, non-
randomized controlled trials as well as RCTs were included
where identiﬁed. Not all opinions might be equally represented
from this type of approach. However, a wide range of stakeholders
and groups were involved, including patients. Effort was made to
ensure diversity; pre-appointed facilitators and reporters with
note-keeping and voice recording of sessions ensured a trans-
parent and consistent process. More detailed discussions on con-
siderations of recruitment/randomization/allocation concealment
strategies were beyond our scope54.
In summary, these initial considerations provide a starting
point for further work in this area. These points are intended to be
complimentary to, and should be considered alongside, OARSI
Clinical Trials Recommendations on prevention of joint injury, the
design, analysis and reporting of OA RCTs and clinical re-
quirements for development of therapeutics in OA7,50,51,55. The
regulatory considerations for a new indication of preventing
symptoms or OA structural change following joint injury are
unique. Engagement with both regulators and the pharmaceuticalindustry is essential if the area is to progress and overcome current
hurdles. Although such trial designs may be challenging, in order
to develop new therapeutics with the aim of patient beneﬁt, the
consensus was that progress in this area is both possible and ur-
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